Future Hope for stage 4 patients

The team at Lifebridge 10000 continues building its patent-pending LB10000 device, built from the ground up for late-stage cancer patients with metastatic disease in two or more locations on the body at once. Future patients treating metastatic cancer with Tumor Treating Fields (TTF) will not be left with the painful decision of what cancer to treat and which to let grow. 

 

 
Alternative cancer treatment, ways to treat cancer, how can cancer be treated, ways of treating cancer, how is cancer treated
 

OUR SOLUTION

Our patent-pending programmable disc system achieves dynamic reassignment of array elements to solve....   

LEARN MORE→

 
Alternative cancer treatment, ways to treat cancer, how can cancer be treated, ways of treating cancer, how is cancer treated
 

THE SCIENCE

While the understanding of the mechanism of action behind TTF is still evolving, the latest compelling research comes from a Harvard study. 

LEARN MORE→

 
Alternative cancer treatment, ways to treat cancer, how can cancer be treated, ways of treating cancer, how is cancer treated
 

ABOUT

We started by trying to save one life and discovered the potential to extend the life of thousands. 

LEARN MORE→

LifeBridge 10000’s dynamic delivery of TTF will provide the capability to treat cancer in multiple locations in the body simultaneously, allowing us to offer TTF to stage 4 patients who would otherwise be without hope in the absence of a 4th modality. 

In 2012, the World Health Organization reported 14,000,000 new cancer cases and 8,000,000 cancer deaths globally. Everyday in America, more than 1,600 people die from cancer (ACS). These cancer patients do not survive because the present modalities of treatment, surgery, chemotherapy, and radiation eventually fail. At that point, a patient's cancer is recurring and non-responsive. A company called NovoCure offers new hope for cancer victims by introducing tumor treating fields as the 4th modality for treating cancer. This emerging therapy has already been recommended as a standard of care for Glioblastoma patients by the National Comprehensive Cancer Network. However, their static form of delivering TTF is best suited for treating tumors in only one location. LifeBridge 10000’s dynamic delivery of TTF will provide the capability to treat cancer in multiple locations in body simultaneously, allowing us to offer TTF to stage 4 patients who would otherwise be without hope in the absence of a 4th modality.